Back to results
US 12,728,164 B2Granted
Methods for treating cancer using x-ray-induced near infrared photoimmunotherapy
AssigneesUniversity of South Florida, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsStephen Edward Saddow, Peter L. Choyke, Marco Vittorio Nardi, Giancarlo Salviati
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of cancers, in particular deep-tissue cancers, using x-ray induced near-infrared photoimmunotherapy are described herein.
Claims15
A method for the treatment of a cancer in a subject in need thereof comprising:
- (a) administering a therapeutically effective amount of a near-infrared antibody-photoabsorber conjugate (APC) to the subject, wherein upon administration the near-infrared APC is at least partially taken up into the cancer tissue and binds to a cell surface protein present within the cancer tissue;
- (b) administering a therapeutically effective amount of an X-ray absorbing nanostructure (NS) to the subject, wherein the X-ray absorbing NS is at least partially taken up into the cancer tissue upon administration;
- (c) exposing the cancer tissue to X-ray radiation, wherein upon exposure of the cancer tissue to the X-ray radiation, the X-ray absorbing NS absorbs the X-ray radiation and emits near-infrared (NIR) light;
- and
- wherein the X-ray absorbing nanostructure comprises silica (SiO2), hydroxyapatite (HA), zinc-gallium-oxide (ZGO), silicon carbide (SiC), or a combination thereof,
- and is doped with a dopant selected from europium (Eu3+), chromium (Cr3+), gold (Au), other x-ray absorbing heavy element dopants, or a combination thereof;
- and wherein the dopant is present in an amount of from 0.01 to 10% by weight, based on the total weight of the X-ray absorbing nanostructure;
- and
- wherein the emitted near-infrared light has a peak wavelength between about 650 nm and about 750 nm that overlaps an absorption band of the APC and is emitted in an amount effective to induce cancer cell death at an X-ray dose of from about 0.1 Gy to about 2.0 Gy.
6 more elements
A method for the treatment of a cancer in a subject in need thereof comprising:
- (a) administering a therapeutically effective amount of a near-infrared antibody-photoabsorber conjugate (APC) to the subject, wherein upon administration the near-infrared APC is at least partially taken up into the cancer tissue and binds to a cell surface protein present within the cancer tissue;
- (b) exposing the cancer tissue to near-infrared (NIR) light;
- (c) administering a therapeutically effective amount of an X-ray absorbing nanostructure (NS) to the subject, wherein the X-ray absorbing NS is at least partially taken up into the cancer tissue upon administration;
- and
- (d) exposing the cancer tissue to X-ray radiation, wherein upon exposure of the cancer tissue to X-ray radiation, the X-ray absorbing NS absorbs the X-ray radiation and emits NIR light;
- and
- wherein the X-ray absorbing nanostructure comprises silica (SiO2), hydroxyapatite (HA), zinc-gallium-oxide (ZGO), silicon carbide (SiC), or a combination thereof,
- and is doped with a dopant selected from europium (Eu3+), chromium (Cr3+), gold (Au), other x-ray absorbing heavy element dopants, or a combination thereof;
- and wherein the dopant is present in an amount of from 0.01 to 10% by weight, based on the total weight of the X-ray absorbing nanostructure;
- and
- wherein the emitted near-infrared light has a peak wavelength between about 650 nm and about 750 nm that overlaps an absorption band of the APC and is emitted in an amount effective to induce cancer cell death at an X-ray dose of from about 0.1 Gy to about 2.0 Gy.
8 more elements
Dependencies are inferred from the claim text.